Johnson & Johnson (NYSE:JNJ) is Banque Cantonale Vaudoise’s 7th Largest Position

Banque Cantonale Vaudoise lifted its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 6.4% in the fourth quarter, HoldingsChannel reports. The firm owned 171,388 shares of the company’s stock after buying an additional 10,376 shares during the period. Johnson & Johnson makes up about 1.6% of Banque Cantonale Vaudoise’s portfolio, making the stock its 7th biggest holding. Banque Cantonale Vaudoise’s holdings in Johnson & Johnson were worth $30,277,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Glassy Mountain Advisors Inc. acquired a new position in Johnson & Johnson in the fourth quarter valued at about $35,000. Retirement Financial Solutions LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at about $40,000. TD Capital Management LLC acquired a new position in Johnson & Johnson in the third quarter valued at about $48,000. VitalStone Financial LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at about $52,000. Finally, Iron Horse Wealth Management LLC lifted its position in Johnson & Johnson by 112.8% in the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after buying an additional 159 shares during the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $154.41 on Friday. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.49. The firm has a market cap of $401.27 billion, a PE ratio of 32.30, a price-to-earnings-growth ratio of 2.67 and a beta of 0.53. The company’s 50 day simple moving average is $159.89 and its 200-day simple moving average is $165.86. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $183.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. The business had revenue of $24.75 billion for the quarter, compared to analyst estimates of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The company’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period last year, the firm posted $2.67 earnings per share. As a group, equities analysts predict that Johnson & Johnson will post 10.66 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be given a dividend of $1.19 per share. The ex-dividend date of this dividend is Monday, May 22nd. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.08%. Johnson & Johnson’s dividend payout ratio (DPR) is 99.58%.

Insider Transactions at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of the stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. TheStreet cut shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, May 19th. Piper Sandler reduced their price target on shares of Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Credit Suisse Group increased their price target on shares of Johnson & Johnson from $168.00 to $170.00 in a research report on Friday, May 5th. Finally, StockNews.com started coverage on shares of Johnson & Johnson in a research note on Thursday, May 18th. They set a “strong-buy” rating on the stock. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $173.00.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.